Sarepta to charge $300K for Duchenne drug that might not even work: 'We tried to be reasonable'

The newly approved Sarepta Therapeutics drug for Duchenne muscular dystrophy will cost about $300,000 a year for the average patient in the United States, which is less than what some Wall Street analysts had expected. Sarepta CEO Dr. Edward Kaye said the pricing was "in the middle of the range" for rare disease drugs. "And given…